On October 21, 2025, A.I.dvisor detected a Broadening Top Pattern (Bullish) for Avadel Pharmaceuticals plc (AVDL, $17.87). On October 21, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $21.74. 23 days later, on November 13, 2025, AVDL reached the target price resulting in a for traders who took a long position in the stock.
AVDL's Aroon Indicator triggered a bullish signal on November 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 171 similar instances where the Aroon Indicator showed a similar pattern. In of the 171 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on October 15, 2025. You may want to consider a long position or call options on AVDL as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AVDL just turned positive on November 14, 2025. Looking at past instances where AVDL's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
AVDL moved above its 50-day moving average on October 15, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AVDL crossed bullishly above the 50-day moving average on October 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where AVDL advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVDL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AVDL broke above its upper Bollinger Band on November 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AVDL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.989) is normal, around the industry mean (18.491). P/E Ratio (0.000) is within average values for comparable stocks, (71.901). AVDL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.834). AVDL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (9.200) is also within normal values, averaging (55.234).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric